AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02948959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Trial: NCT05258123
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with nine tables was administered
Trial: NCT02372760
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy
Trial: NCT00845507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Sterile solution in equivalent doses as Exenatide
Trial: NCT01425853
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT02239081
Drug: Placebo for CTP-730
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01545440
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous dose every 4 weeks
Trial: NCT02618720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02382653
Drug: oral perixicam
RxNorm normalized name: piroxicam Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral adminstration of buccal perixicam
Trial: NCT01583738
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02080195
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
Trial: NCT01646853
Drug: cisplatin-fluorouracil chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
Trial: NCT02632786
Drug: NEOD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Trial: NCT02632786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Bag
Trial: NCT01513863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied to affected area once a day for 70 days
Trial: NCT01606397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (capsule)
Trial: NCT00927355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician.
Trial: NCT01069081
Drug: Arm C
RxNorm normalized name: Forearm Crutch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
Trial: NCT01069081
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
Trial: NCT01069081
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
Trial: NCT04700475
Drug: citric acid solution
RxNorm normalized name: citric acid Topical Solution
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: citric acid solution applied as a mouth rinse
Trial: NCT03072225
Drug: Herbal Medicine C-117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Medicine C-117 formula including 2 herbals and 2 insects
Trial: NCT03072225
Drug: The Placebo of Herbal Medicine C-117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo of Herbal Medicine C-117 formula including 4 herbals
Trial: NCT00961896
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT00961896
Drug: LDE225 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00961896
Drug: LDE225 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03541044
Drug: Nicorette Mini Lozenge
RxNorm normalized name: Nicorette Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Trial: NCT01872910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01872910
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03304873
Drug: Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
Trial: NCT00100932
Drug: E7389 21 Day Cycle
RxNorm normalized name: Ortho-Cyclen 21 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
Trial: NCT01101334
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017, Two 0.25mg Tablets administered twice daily
Trial: NCT03158935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
Trial: NCT00538096
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Trial: NCT00538096
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Trial: NCT00538096
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Trial: NCT00988221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to tocilizumab was supplied as a sterile solution in vials.
Trial: NCT02948881
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02006121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 9 mg/ml
Trial: NCT00815035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat flour used as a placebo that is orally ingested a graded fashion
Trial: NCT01904136
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02923999
Drug: P2G12 Dose Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
Trial: NCT02923999
Drug: P2G12 Dose Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
Trial: NCT02923999
Drug: P2G12 Dose Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
Trial: NCT00001202
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04018885
Drug: ALA 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Trial: NCT04018885
Drug: ALA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Trial: NCT04018885
Drug: ALA 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Trial: NCT01367249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile ophthalmic solution
Trial: NCT00154310
Drug: Enteric-coated mycophenolate sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
Trial: NCT00310323
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 4 ounces of Coca-Cola
Trial: NCT00035802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
Trial: NCT03625739
Drug: anti-tuberculosis drug
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention drugs are prescribed by treating caregiver
Trial: NCT03866980
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01115985
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00790153
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral suspension given at one occasion.
Trial: NCT00439829
Drug: Gonal F
RxNorm normalized name: Gonal F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.
Trial: NCT01222468
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
Trial: NCT00211978
Drug: calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
Trial: NCT00211978
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
Trial: NCT03101241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04203537
Drug: CA-008
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration during surgery
Trial: NCT04203537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration during surgery
Trial: NCT00562185
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01257412
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/10 mg Oral dose od
Trial: NCT02306083
Drug: Placebo three times a day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02306083
Drug: glucosamine sulfate 1500 mg three times a day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01454453
Drug: Patients- dose titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose titration (patients) - 4-10 weeks
Trial: NCT03395249
Drug: SPR994
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1.
Trial: NCT03395249
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Trial: NCT03395249
Drug: Orapenem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil granules
Trial: NCT03604757
Drug: 68Ga-PSMA-617 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT Imaging with 68Ga-PSMA-617 injection
Trial: NCT03604757
Drug: 68Ga-RM2 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT Imaging with 68Ga-RM2 injection
Trial: NCT02906995
Drug: Sublingual tablet 4 mg versus Nicorette Lozenge 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge.
Trial: NCT01336959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose matching placebo administered 2 prior to surgery
Trial: NCT02330562
Drug: BEV
RxNorm normalized name: Bevespi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
Trial: NCT01849419
Drug: Within-subjects (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
Trial: NCT01921777
Drug: Traumeel
RxNorm normalized name: Traumeel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Trial: NCT03863899
Drug: Additional intraoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of any analgesics during the operation
Trial: NCT03863899
Drug: Additional postoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of any analgesics within first 24 hours after the operation
Trial: NCT05212493
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis oil 20:1 CBD:THC ratio
Trial: NCT03326947
Drug: docetaxel, cisplatin and 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy
Trial: NCT00003175
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01921777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Trial: NCT03779087
Drug: 10d TL quadruple therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
Trial: NCT03779087
Drug: 10d AL quadruple therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
Trial: NCT02171741
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous daily dosing for 20 or 13 days
Trial: NCT02819687
Drug: RDX5791
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02819687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002757
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002757
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002757
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002757
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002757
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02501213
Drug: Spironolactone (+/- Furosemide)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
Trial: NCT00702650
Drug: Testosterone MD-Lotion
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg to 120 mg administered topically once daily for 120 days
Trial: NCT03017313
Drug: LHRH analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-or 6-month formulations
Trial: NCT04097405
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Trial: NCT00535743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
Trial: NCT00688272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given QD x 6 days
Trial: NCT00535743
Drug: Esmeron®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Trial: NCT00877903
Drug: Prochymal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
Trial: NCT00877903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of excipients of Prochymal®
Trial: NCT03283696
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00332605
Drug: Naltrexone plus N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT00332605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT01309243
Drug: FTC/RPV/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal